Infectious Disease· Topic 7.9 HIV transmission, prevention, and prophylaxis· 7.9.4

HIV in pregnancy

HIV in pregnancy is managed by starting or continuing combination antiretroviral therapy in every HIV-positive pregnant patient regardless of CD4 count or gestational age, because fully suppressive ART drives perinatal transmission below 1%, versus 25 to 30% with no intervention at all.

12 min read7 practice questions8 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    A perinatal transmission problem with a near-curative fix: combination antiretroviral therapy (ART) that fully suppresses the maternal human immunodeficiency virus (HIV) viral load cuts…

  • Epidemiology

    Untreated vertical transmission is 25 to 30%, mostly via intrapartum exposure; combination ART reduces this to under 1%, far more effective than zidovudine monotherapy alone (about 25% to about 8%), which is never used alone.

  • Risk factors

    No maternal antiretroviral therapy: the largest driver of transmission; an untreated mother carries the full 25 to 30% baseline risk.

  • Pathophysiology

    HIV is a retrovirus that integrates into the host genome: a single-stranded, positive-sense, enveloped RNA virus (family Retroviridae); after cell entry, reverse transcriptase converts the RNA genome…

  • Clinical features

    Most pregnant patients with HIV are asymptomatic: identified by routine opt-out prenatal screening rather than symptoms.

  • Differential diagnosis

    Acute retroviral syndrome versus another viral syndrome (mononucleosis, influenza, viral hepatitis): fever, pharyngitis, and lymphadenopathy overlap; discriminator is a fourth-generation HIV…

  • Diagnosis

    Diagnosis is established by a positive fourth-generation HIV-1/2 antigen/antibody combination immunoassay confirmed by an HIV-1/HIV-2 antibody differentiation immunoassay: a reactive screen is…

  • Management

    First, start (or continue) combination ART immediately upon diagnosis, regardless of trimester, CD4 count, or viral load: a patient already on effective ART continues the same regimen; a…

  • Complications

    Perinatal transmission and infant infection: the central complication this pathway prevents; an infected infant requires lifelong ART and ongoing specialty care.

  • Prognosis

    The infant's prognosis hinges on the same lever throughout: transmission risk falls from 25 to 30% to under 1% with fully suppressive ART, delivery-route selection, and breastfeeding avoidance when…

  • Prevention

    Universal opt-out HIV screening at the first prenatal visit, using the fourth-generation antigen/antibody combination immunoassay, so ART can start as early as possible.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.